Rolf A Stahel

Rolf A Stahel

UNVERIFIED PROFILE

Are you Rolf A Stahel?   Register this Author

Register author
Rolf A Stahel

Rolf A Stahel

Publications by authors named "Rolf A Stahel"

Are you Rolf A Stahel?   Register this Author

73Publications

1584Reads

36Profile Views

Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.

J Thorac Cardiovasc Surg 2019 Aug 22. Epub 2019 Aug 22.

Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2019.07.073DOI Listing
August 2019

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

ESMO Open 2017 3;2(3):e000187. Epub 2017 Aug 3.

European Society for Medical Oncology (ESMO), Clinic of Oncology,University Hospital, Zürich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634488PMC
August 2017

Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.

Lung Cancer 2016 Apr 28;94:40-5. Epub 2016 Jan 28.

Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.01.017DOI Listing
April 2016

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.

J Thorac Oncol 2015 Nov;10(11):1634-41

*Division of Thoracic Surgery, †Department of Diagnostic Radiology, University Hospital Zurich, Zurich, Switzerland; ‡Department of Biostatistics, Epidemiology, Biostatistics and Prevention Unit, University Zurich, Zurich, Switzerland; §Division of Thoracic Surgery, Medical University Vienna, Vienna, Austria; and ‖Laboratory of Molecular Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000661DOI Listing
November 2015

Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.

Lung Cancer 2015 Jan 6;87(1):77-9. Epub 2014 Nov 6.

Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital of Zürich, Häldeliweg 4, 8044 Zürich, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.10.017DOI Listing
January 2015

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

J Thorac Oncol 2014 Nov;9(11):1675-84

*Centre Hospitalier Universitaire de Vaud, Lausanne, Switzerland; †Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; ‡Frontier Science Foundation-Hellas & University of Athens, Athens, Greece; §Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ‖Institute for Pathology, University Hospital Basel, Basel, Switzerland; ¶Department of Oncology, University Hospital, Aarhus, Denmark; #Department of Medical Oncology, St. James's Hospital, Dublin, Ireland; **Medical University of Gdansk, Gdansk, Poland; ††University Hospital KU Leuven, Leuven, Belgium; ‡‡Vall d'Hebron University Hospital, Barcelona, Spain; §§Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; ‖‖Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; ¶¶VU University Medical Center, Amsterdam, Netherlands; ##Maastricht University Medical Centre, Maastricht, Netherlands; ***Manchester University and The Christie National Health Services Foundation Trust, Manchester, United Kingdom; †††Netherlands Cancer Institute, Amsterdam, Netherlands; ‡‡‡Department of Medicine, University of Valencia and Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; §§§Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; and ‖‖‖Clinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000320DOI Listing
November 2014

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

J Clin Oncol 2014 Sep 28;32(25):2780-7. Epub 2014 Jul 28.

Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5921DOI Listing
September 2014

GAS5 long non-coding RNA in malignant pleural mesothelioma.

Mol Cancer 2014 May 23;13:119. Epub 2014 May 23.

Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039656PMC
May 2014

[In Process Citation].

Praxis (Bern 1994) 2013 Apr;102(9):503-12

Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/1661-8157/a001306DOI Listing
April 2013

Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.

PLoS One 2012 17;7(9):e45354. Epub 2012 Sep 17.

Laboratory of Molecular Oncology, University Hospital of Zürich, University of Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0045354PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444484PMC
February 2013

Role of hedgehog signaling in malignant pleural mesothelioma.

Clin Cancer Res 2012 Sep 25;18(17):4646-56. Epub 2012 Jun 25.

Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, Division of Thoracic Surgery, Institute of Surgical Pathology, University Hospital Zürich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-0599DOI Listing
September 2012

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Eur J Cancer 2012 May 6;48(7):961-73. Epub 2012 Mar 6.

University of Torino San Luigi Hospital, Orbassano, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.02.001DOI Listing
May 2012

Proteomic surfaceome analysis of mesothelioma.

Lung Cancer 2012 Feb 10;75(2):189-96. Epub 2011 Aug 10.

Clinic of Oncology, University Hospital Zürich, 8044 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.07.009DOI Listing
February 2012

Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.

Eur J Radiol 2012 Jan 3;81(1):e19-25. Epub 2010 Dec 3.

Department of Internal Medicine, Clinic for Medical Oncology, University Hospital Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0720048X1000551
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2010.11.006DOI Listing
January 2012

Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.

Neoplasia 2011 Oct;13(10):961-70

Laboratory of Molecular Oncology, Clinic and Polyclinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201572PMC
http://dx.doi.org/10.1593/neo.11828DOI Listing
October 2011

Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.

Appl Immunohistochem Mol Morphol 2011 Mar;19(2):99-105

Institute for Surgical Pathology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0b013e3181f1feebDOI Listing
March 2011

Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.

Eur J Cancer 2011 Jan 29;47(2):326-32. Epub 2010 Oct 29.

Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hospital of Zürich, Häldeliweg 4, 8044 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.09.044DOI Listing
January 2011

Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.

Lung Cancer 2010 Mar 30;67(3):311-7. Epub 2009 May 30.

Department of Medical Radiology, University Hospital Zuerich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.04.015DOI Listing
March 2010

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Respir Med 2010 Jan 8;104(1):142-8. Epub 2009 Oct 8.

Department of Pneumology and Thoracic Surgery, Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2009.07.019DOI Listing
January 2010

Successful publishing: how to get your paper accepted.

Surg Oncol 2009 Dec 11;18(4):350-6. Epub 2008 Oct 11.

Surgical Oncology, Editor.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2008.09.001DOI Listing
December 2009

Functional inactivation of NF2/merlin in human mesothelioma.

Lung Cancer 2009 May 4;64(2):140-7. Epub 2008 Oct 4.

Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hospital of Zürich, Häldeliweg 4, 8044 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2008.08.014DOI Listing
May 2009

Malignant pleural mesothelioma.

Future Oncol 2009 Apr;5(3):391-402

Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hosptial, CH-8091 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.09.7DOI Listing
April 2009

Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?

Curr Opin Oncol 2009 Mar;21(2):124-30

Clinic and Policlinic of Oncology and Thoracic Surgery, University Hospital, Zürich CH 8091, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328324bc30DOI Listing
March 2009

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Mol Cancer 2007 Oct 22;6:66. Epub 2007 Oct 22.

Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hospital of Zürich, Häldeliweg 4, 8044 Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-6-66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2134932PMC
October 2007

Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results.

Lung Cancer 2007 Sep 21;57(3):282-91. Epub 2007 May 21.

Clinic and Policlinic of Oncology, Laboratory of Molecular Oncology, University Hospital, Haeldeliweg 4, CH-8044 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016950020700192
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2007.03.025DOI Listing
September 2007

Malignant pleural mesothelioma: a new standard of care.

Authors:
Rolf A Stahel

Lung Cancer 2006 Dec 23;54 Suppl 2:S9-S14. Epub 2006 Oct 23.

Clinic and Policlinic for Oncology/Department of Internal Medicine, University Hospital, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.09.011DOI Listing
December 2006

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

Cancer Chemother Pharmacol 2006 Apr 29;57(4):533-9. Epub 2005 Jul 29.

Clinic and Policlinic of Oncology, University Hospital, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0070-zDOI Listing
April 2006

A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.

Oligonucleotides 2004 ;14(3):199-209

Molecular Oncology Laboratory, Department of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/oli.2004.14.199DOI Listing
August 2005

The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line.

Carcinogenesis 2004 Oct 20;25(10):1839-46. Epub 2004 May 20.

Forschungslabor Molekulare Onkologie, Klinik und Poliklinik für Onkologie, Universitaetsspital Zurich, Haeldeliweg 4, CH-8044 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgh190DOI Listing
October 2004

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

J Clin Oncol 2004 Oct;22(20):4157-64

Zurich University Hospital, Clinic and Policlinic of Oncology, Laboratory of Molecular Oncology, Haeldeliweg 4, 8044 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.11.123DOI Listing
October 2004

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.

J Clin Oncol 2004 Sep;22(17):3451-7

Division of Thoracic Surgery and Policlinic for Radiation Oncology, University Hospital, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.10.071DOI Listing
September 2004

Management and costs of treating lung cancer patients in a university hospital.

Pharmacoeconomics 2004 ;22(7):435-44

Department of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00019053-200422070-00003DOI Listing
July 2004

False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer.

Oncology 2004 ;66(4):336-8

Clinic and Policlinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000078336DOI Listing
July 2004

Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer.

Lung Cancer 2004 May;44(2):143-7

Department of Oncology, University Hospital Zürich, Rämistrasse 100, CH-8091 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2003.11.004DOI Listing
May 2004

Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.

Int J Cancer 2003 Aug;106(2):160-6

Division of Medical Oncology, Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11209DOI Listing
August 2003

Antisense oligonucleotides for cancer therapy-an overview.

Lung Cancer 2003 Aug;41 Suppl 1:S81-8

Division of Medical Oncology, University Hospital, Rämistrasse 100, Zurich 8091, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00147-8DOI Listing
August 2003

Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR.

J Immunother 2003 Jan-Feb;26(1):41-6

Division of Oncology, Department of Internal Medicine, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland.

View Article

Download full-text PDF

Source
June 2003

Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.

Breast Cancer Res Treat 2002 Nov;76(2):157-66

Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1020543004400DOI Listing
November 2002

Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology.

J Immunother 2002 May-Jun;25(3):264-8

Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.

View Article

Download full-text PDF

Source
October 2002

Circulating DNA: a new diagnostic gold mine?

Cancer Treat Rev 2002 Oct;28(5):255-71

Departement für Innere Medizin, Onkologie Abteilung, Universitätsspital Zürich, Haeldeliweg 4, Switzerland.

View Article

Download full-text PDF

Source
October 2002

Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.

Biochim Biophys Acta 2002 Jun;1576(1-2):101-9

Division of Medical Oncology, Department of Internal Medicine, University Hospital of Zürich, Haldiweg 4, CH-8044 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0167-4781(02)00300-7DOI Listing
June 2002

Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.

Lung Cancer 2002 May;36(2):151-8

Division of Oncology, Department of Internal Medicine, University Hospital Zürich, Rämistrasse 100, 8091, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(01)00478-0DOI Listing
May 2002

Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.

J Invest Dermatol 2002 Mar;118(3):505-12

Division of Oncology, Department of Internal Medicine, University Hospital Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.0022-202x.2001.01677.xDOI Listing
March 2002